News
Biogen to acquire Apellis in $5. 6bn deal
4+ hour, 57+ min ago (271+ words) Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5. 6bn. The deal includes two commercialised, differentiated immunology and rare disease medicines, Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection) that will add immediate sales revenue to Biogen, increasing the company's short and long-term…...
Gilead to acquire Tubulis for up to $5bn
1+ day, 4+ hour ago (283+ words) As part of the agreement, Gilead will pay $3. 15bn upfront, with an option of up to $1. 85bn in milestone payments. Daniel O'Day, Chairman and CEO of Gilead, said: "The agreement to acquire Tubulis is a significant milestone in Gilead's progress in oncology....
Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development
1+ day, 7+ hour ago (302+ words) The Pistoia Alliance, a global, not-for-profit alliance advancing collaboration in life sciences R&D, is launching new patient research to shape the ethical use of social media listening in drug development, as part of its'Social Media Real-World Evidence (RWE) project....
Pharma Quest returns: EPA perspectives, through a rare disease lens
2+ day, 6+ hour ago (133+ words) April 7, 2026 |EPA, First'in'class innovation, Pharma Quest, Quality of life (Qo L), ispor, rare diseases Together, these shared preferences point to an aligned set of decision-making principles that extend across stakeholder groups and conference settings. Therapy areas prioritized for ideal drug design…...
Lilly's Foundayo approved by US FDA as oral GLP-1 for weight loss
2+ day, 4+ hour ago (329+ words) Eli Lilly's Foundayo (orforglipron), the only oral GLP-1 weight loss treatment that can be taken at any time of the day with no food or water restrictions, has been approved by the US FDA for adults with obesity, or who…...
Roche opens new Swiss Institute of Human Biology research facility
1+ week, 6+ hour ago (284+ words) Roche has opened a new research facility for the Institute of Human Biology (IHB) in Basel, Switzerland. The building will have a total floor area of 23, 000sqm over eight floors, and accommodate up to 250 IHB researchers. Roche is currently investing 1. 5bn euros…...
Insight gaps leave Biopharma vulnerable to patent cliff crisis, warns expert
1+ week, 1+ day ago (216+ words) With unprecedented patent cliffs looming, putting an estimated $200 to $400 billion in annual global sales at risk, senior strategy consultant and Nmblr founder, Janice Mac Lennan, is issuing a stark warning to biopharma organisations tasked with delivering innovative new therapies to…...
Poolbeg Pharma appoints Adrian Kilcoyne to Scientific Advisory Board
1+ week, 1+ day ago (199+ words) Bringing over 20 years of experience with strategic drug development leadership to the role, Kilcoyne is currently Chief Medical Officer (CMO) at Cellectis, focusing on the development of allogenic CAR-T therapies. Other former roles include CMO at Humanigen, where he helped…...
Google News
1+ week, 2+ day ago (11+ words) Pharma's content paradox: why more content is not the answer'PMLi VE...
Novo Nordisk's Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes
1+ week, 2+ day ago (246+ words) Novo Nordisk's Awiqli (insulin icodec) has been approved by the US FDA as the first and only once-weekly, long-acting basal insulin for adults with type 2 diabetes (T2 D). Awiqli works alongside diet and exercise to improve blood sugar control in adults with…...